Written from the studies on PubMed, searched on 12 Nov 2026. Every number below comes from a study listed under Sources. The text was written by AI from these studies; each sentence names the studies it comes from.
The claim
Posts say that eliglustat, a daily capsule, helps people with Gaucher disease by cutting the build-up of fatty substances in the body.
Where research stands
We found 68 published papers on eliglustat and Gaucher disease. They were published between 2010 and 2026. 17 of them are studies in people. The papers do not say how many people took part. 10 of them compared people who got it with a group that did not. 5 were studies in animals, and 2 were only in cells in the lab. 11 papers are reviews that sum up other studies. 1 new study in people is running or will start soon, says the trial register ClinicalTrials.gov.
- 17In people10 with a comparison group
- 5In animals
- 2Only in the lab
What the studies found
Trials in people
In the ENGAGE trial, adults with type 1 Gaucher disease who had not been treated before took eliglustat or a placebo; after 9 months, those on eliglustat had better organ volumes and blood counts than those on placebo. [1][2] Among 13 patients followed for 4.5 years, the authors report the average spleen volume fell by 66% and the average liver volume by 23%. [1] In the same group, the authors report average hemoglobin rose by 1.4 g/dl and average platelet count rose by 87%. [1] In the ENCORE trial, eliglustat was found to be as good as an injected enzyme treatment (imiglucerase) at keeping blood counts and spleen and liver size steady for one year in people who were already stable. [3] After the first year, 157 ENCORE patients all took eliglustat; the authors report these measures stayed steady for up to 4 years, though only 46 patients had reached 4 years. [3] In the EDGE trial, 131 patients who had reached treatment goals were randomly given eliglustat once or twice a day; after one year, 80.4% of once-daily and 83.1% of twice-daily patients were still stable. [4] A pooled look at four trials of 393 adults (1400 patient-years of use) found 97% of side effects were mild or moderate, and 2.3% of patients left a trial because of side effects linked to the drug. [5]
Other studies in people
In a phase 2 trial, 26 untreated adults took eliglustat for up to 8 years; the 19 who finished had average spleen volume down 69% and liver volume down 34%, with no control group. [6] Among eliglustat trial participants, 18 women had 19 unplanned pregnancies; 14 healthy infants were born from 13 of these, and eliglustat was stopped quickly once pregnancy was found. [7] Small studies of a single dose in people with liver or kidney problems found higher drug levels with moderate liver problems, which led to a change in the drug label. [8] A study in China of 19 adults, followed a median of 7 months without a control group, reported lower glucosylsphingosine, a marker of the disease, and a smaller liver. [9] A 52-week study of 5 adults in China, all with a certain gene type, reported lower disease markers and smaller liver and spleen, with one person having mild nausea. [10] A case report describes one overweight patient without a spleen whose disease marker rose after switching from enzyme treatment to eliglustat, showing responses can vary. [11]
Reviews
A systematic review of three studies, two of them randomised trials, found no meaningful difference between imiglucerase and eliglustat for hemoglobin, platelets, or liver and spleen size. [12] Expert groups in Europe and the United States have published advice on using eliglustat, noting it is broken down by the CYP2D6 enzyme, so a patient's gene type and other medicines need checking. [13][14]
In animals
In lifetime tests in mice and rats, eliglustat did not raise the number of tumours. [15] Several mouse studies tested new drugs built on eliglustat or similar drugs that reach the brain, because eliglustat itself is aimed at the body, not the brain. [16][17][18]
In the lab
In human kidney cells grown in a dish, eliglustat reduced the damage caused by Shiga toxin 2, a finding far from any use in people. [19]
Verdict
Eliglustat has been tested in randomised trials in people with Gaucher disease.
What this means for you: A study in people is not proof that it helps you. Do not stop or change your medicines because of it. Ask your doctor before you start taking it.
Sources
- Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.2021 · Am J Hematol · Randomised trial
- Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.2017 · Am J Hematol · Randomised trial
- Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.2017 · Blood · Randomised trial
- Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.2018 · Mol Genet Metab · Randomised trial
- Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.2019 · Orphanet J Rare Dis · Randomised trial
- Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.2019 · Am J Hematol · Study in people
- Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials.2021 · JIMD Rep · Study in people
- Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1.2020 · Mol Genet Metab · Study in people
- Real-World Effectiveness and Safety of Eliglustat in Adult Patients with Gaucher Disease Type 1: A Multicenter Retrospective Study in China.2026 · J Clin Med · Other paper
- [Efficacy and safety of eliglustat tartrate in adults with Gaucher disease type 1].2026 · Zhonghua Yi Xue Za Zhi · Other paper
- Increased Lyso-Gb1 Levels in an Obese Splenectomized Gaucher Disease Type 1 Patient Treated with Eliglustat: Unacknowledged Poor Compliance or Underlying Factors.2025 · Metabolites · Other paper
- The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review.2018 · J Res Pharm Pract · Review
- Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.2017 · Eur J Intern Med · Review
- Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.2016 · Mol Genet Metab · Review
- Carcinogenicity testing of eliglustat in mice and rats.2015 · Regul Toxicol Pharmacol · In animals
- Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.2020 · ACS Chem Neurosci · In animals
- A new brain-penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease.2021 · J Neurochem · In animals
- Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease.2012 · PLoS One · In animals
- Eliglustat prevents Shiga toxin 2 cytotoxic effects in human renal tubular epithelial cells.2022 · Pediatr Res · In the lab
